Atrial fibrillation in stroke - Utility of Neuroimaging Evaluation

A registry of clinical and MRI outcomes following early versus late initiation of anticoagulation after ischaemic stroke or transient ischaemic attack in patients with atrial fibrillation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN44617730

Enrollment

280

Registered

2018-05-15

Start date

2016-05-21

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischaemic stroke Circulatory System Acute ischaemic stroke

Interventions

This is a prospective, 3-month observational cohort study using an established clinico-radiological stroke registry to examine clinical and MR imaging outcomes of patients initiated on novel oral anti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who present with an acute ischaemic stroke or TIA of cardioembolic (atrial fibrillation [AF]-related) origin and who have an MRI following their primary ischaemic event, and are deemed suitable for initiation of NOAC or VKA therapy 2. Subjects must be enrolled within 30 days of symptom onset

Exclusion criteria

Exclusion criteria: 1. Evidence of primary intracranial haemorrhage 2. Inability to have baseline and follow-up MRI

Design outcomes

Primary

Measure	Time frame
New ischaemic lesions on MRI at 1 month	—

Secondary

Measure	Time frame
1. New clinical stroke within 90 days determined by clinic review or telephone follow up 2. Intracerebral haemorrhage on MRI at 1 month 3. Disability or dependence following stroke, assessed by mRS at 90 days determined by clinic review or telephone follow up 4. Non-intracranial bleeding within 90 days	—

Countries

Australia

Contacts

Public ContactChristina Lam

Christina.lam@mh.org.au+61 410 858 739

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026